Mitoconix Bio is pioneering a novel strategy
to improve mitochondrial health
Develops disease-modifying therapeutics for neurodegenerative diseases
Mitoconix Bio is an emerging biopharmaceutical company developing disease modifying therapies addressing unmet medical need by improving mitochondrial health.
Established in August 2016 at the FutuRx incubator, Mitoconix Bio’s lead program is based on the breakthrough scientific discoveries of its founder Daria Mochly-Rosen at Stanford University. The Stanford team has identified the molecular-based pathological interactions leading to excess mitochondrial fragmentation and identified pharmacological inhibitors of excess fission. Mitoconix exclusively licensed the technology from Stanford University.